We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
#73 - AMA #9: NAD & metformin, fat-burning zone, creatine, estrogenization of men, emergency kit for cold & flu, and more
Access AI content by logging in
In this “Ask Me Anything” (AMA) episode, Peter answers a wide range of questions from subscribers. Bob Kaplan, Peter’s head of research, asks the questions. If you’re not a subscriber and listening on a podcast player, you’ll only be able to hear a preview of the AMA.
If you’re a subscriber, you can now listen to this full episode on your private RSS feed. You can also watch (or listen) to this full episode on our website at the AMA #9 show notes page.
Questions continue to be pulled from the AMA section on the website, and any subscriber is welcome to submit questions for future AMAs.
We discuss:
- The story of how Peter almost worked for Theranos [2:00];
- The trend of lower testosterone and higher estrogen in men: Why is it happening and what to do about it? [10:00];
- Takeaways from Peter’s recent hunting trip in Hawaii [14:45];
- What books are you currently reading/listening to? [21:30];
- What advice would you give to the 25 year-old Peter? [24:00];
- What is your emergency protocol if you start getting sick? [27:45];
- How have your thoughts changed on NAD precursors, and also on metformin, in the past year or so? [30:30];
- What are your thoughts on “fat burning” zones for cardio workouts? — A lesson in relative vs. absolute fat combustion [34:15];
- What mental models do you use and how do you go about solving problems and approaching difficult questions? [49:00];
- Creatine supplementation—Yay or nay? Why? [49:30]; and
- More.
Learn more: https://peterattiamd.com/
Show notes page for this episode: https://peterattiamd.com/ama09/
Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/
Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/
Connect with Peter on Facebook | Twitter | Instagram.